trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Cyclophosphamide is an anticancer prodrug that requires bioactivation to the active alkylating metabolite 4-hydroxycyclophosphamide to exert its antitumor activity.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Cyclophosphamide is an anticancer prodrug that requires bioactivation to the active alkylating metabolite 4-hydroxycyclophosphamide to exert its antitumor activity?

Yes. Cyclophosphamide is widely established in the literature as an anticancer prodrug that requires metabolic bioactivation—primarily via cytochrome P450 enzymes—into 4-hydroxycyclophosphamide to exert its alkylating antitumor activity.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently state and build upon the established pharmacological fact that cyclophosphamide is a prodrug requiring bioactivation to 4-hydroxycyclophosphamide. Multiple studies explicitly confirm this metabolic pathway, making the claim fully supported.

Evidence for · 4
Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics
2024
States that cyclophosphamide is a prodrug mainly bioactivated by cytochrome P450 enzymes to achieve its clinical effects.
Get citation
El-Serafi, I. & Steele, S. (2024). Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics. doi.org. https://doi.org/10.1155/2024/4862706

See more details
More for · 3
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
2021
Investigates the activation of the prodrug cyclophosphamide by cytochrome P450 enzymes into its active metabolite.
Get citation
N, H., M, Y., K, B., M, F., & D, P. (2021). Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.. doi.org. https://doi.org/10.1007/s00280-021-04307-0

DEVELOPMENT AND VALIDATION METHOD OF CYCLOPHOSPHAMIDE AND 4-HYDROXYCYCLOPHOSPHAMIDE WITH 4-HYDROXYCYCLOPHOSPHAMIDE-D4 AS INTERNAL STANDARD IN DRIED BLOOD SPOTS USING UPLC-MS/MS
2021
Identifies cyclophosphamide as an alkylating agent prodrug that is metabolized into its active form, 4-hydroxycyclophosphamide.
Get citation
HASANAH, Y. I. F., HARAHAP, Y., & SURYADI, H. (2021). DEVELOPMENT AND VALIDATION METHOD OF CYCLOPHOSPHAMIDE AND 4-HYDROXYCYCLOPHOSPHAMIDE WITH 4-HYDROXYCYCLOPHOSPHAMIDE-D4 AS INTERNAL STANDARD IN DRIED BLOOD SPOTS USING UPLC-MS/MS. doi.org. https://doi.org/10.22159/ijap.2021v13i2.39590

Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients.
2021
Describes cyclophosphamide as an anticancer alkylating agent and prodrug metabolized to its active metabolite, 4-hydroxycyclophosphamide.
Get citation
YIF, H., Y, H., & DJ, P. (2021). Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients.. doi.org. https://doi.org/10.2147/dddt.s279128

What does the evidence say?

The retrieved papers consistently state and build upon the established pharmacological fact that cyclophosphamide is a prodrug requiring bioactivation to 4-hydroxycyclophosphamide. Multiple studies explicitly confirm this metabolic pathway, making the claim fully supported.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work